Bruce Keyt
2021
In 2021, Bruce Keyt earned a total compensation of $4.6M as Chief Scientific Officer at IGM Biosciences, a 67% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $204,751 |
|---|---|
| Option Awards | $3,341,385 |
| Salary | $455,001 |
| Stock Awards | $599,900 |
| Total | $4,601,037 |
Keyt received $3.3M in option awards, accounting for 73% of the total pay in 2021.
Keyt also received $204.8K in non-equity incentive plan, $455K in salary and $599.9K in stock awards.
Rankings
In 2021, Bruce Keyt's compensation ranked 2,875th out of 12,415 executives tracked by ExecPay. In other words, Keyt earned more than 76.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,875 out of 12,415 | 77th |
Division Manufacturing | 1,144 out of 5,501 | 79th |
Major group Chemicals And Allied Products | 452 out of 2,371 | 81st |
Industry group Drugs | 396 out of 2,092 | 81st |
Industry Pharmaceutical Preparations | 265 out of 1,542 | 83rd |
Source: SEC filing on April 27, 2023.
Keyt's colleagues
We found three more compensation records of executives who worked with Bruce Keyt at IGM Biosciences in 2021.
News
IGM Biosciences CEO Fred Schwarzer's 2022 pay falls 46% to $5.3M
April 27, 2023
IGM Biosciences CEO Fred Schwarzer's 2021 pay jumps 94% to $9.9M
April 27, 2022
IGM Biosciences CEO Fred Schwarzer's 2020 pay jumps 574% to $5.1M
April 29, 2021
IGM Biosciences CEO Fred Schwarzer's 2019 pay jumps 46% to $757K
April 21, 2020